Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,938

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Open access
Luznik, Leo, O'Donnell, Paul V., Symons, Heather J., Chen, Allen R., Leffell, M. Susan, Zahurak, Marianna, Gooley, Ted A., Piantadosi, Steve, Kaup, Michele, Ambinder, Richard F., Huff, Carol Ann, Matsui, William, Bolaños-Meade, Javier, Borrello, Ivan, Powell, Jonathan D., Harrington, Elizabeth, Warnock, Sandy, Flowers, Mary, Brodsky, Robert A., Sandmaier, Brenda M., Storb, Rainer F., Jones, Richard J., Fuchs, Ephraim J.·2008·Biology of Blood and Marrow Transplantation
DOI 10.1016/j.bbmt.2008.03.005
Open this paper in CoChat — free account

Abstract

We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide (Cy) to prevent graft rejection and graft-versus-host disease (GVHD) after outpatient nonmyeloablative conditioning and T cell-replete bone marrow transplantation from partially HLA-mismatched (haploidentical) related donors. Patients with advanced hematologic malignancies (n = 67) or paroxysmal nocturnal hemoglobinuria (n = 1) received Cy 50 mg/kg i.v. on day 3 (n = 28) or on days 3 and 4 (n = 40) after transplantation. The median times to neutrophil (>500/microL) and platelet recovery (>20,000/microL) were 15 and 24 days, respectively. Graft failure occurred in 9 of 66 (13%) evaluable patients, and was fatal in 1. The cumulative incidences of grades II-IV and grades III-IV acute (aGVHD) by day 200 were 34% and 6%, respectively. There was a trend toward a lower risk of extensive chronic GVHD (cGVHD) among recipients of 2 versus 1 dose of posttransplantation Cy (P = .05), the only difference between these groups. The cumulative incidences of nonrelapse mortality (NRM) and relapse at 1 year were 15% and 51%, respectively. Actuarial overall survival (OS) and event-free survival (EFS) at 2 years after transplantation were 36% and 26%, respectively. Patients with lymphoid malignancies had an improved EFS compared to those with myelogenous malignancies (P = .02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbmt.2008.03.005

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 1,938

Metadata

Authors
Luznik, L., O'Donnell, P. V., Symons, H. J., Chen, A. R., Leffell, M. S., Zahurak, M., Gooley, T. A., Piantadosi, S., Kaup, M., Ambinder, R. F., Huff, C. A., Matsui, W., Bolaños-Meade, J., Borrello, I., Powell, J. D., Harrington, E., Warnock, S., Flowers, M., Brodsky, R. A., Sandmaier, B. M., Storb, R. F., Jones, R. J., & Fuchs, E. J.
Venue
Biology of Blood and Marrow Transplantation
Publisher
Elsevier BV
Published
2008-06
Volume
14
Issue
6
Pages
641-650
ISSN
1083-8791 (ISSN-L)
DOI
10.1016/j.bbmt.2008.03.005
OpenAlex
W2039334806
Cited by
1,938
References
5
FWCI
16.60
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. https://app.cochat.ai/papers/10.1016/j.bbmt.2008.03.005
The paper
Luznik, L., O'Donnell, P. V., Symons, H. J., Chen, A. R., Leffell, M. S., Zahurak, M., Gooley, T. A., Piantadosi, S., Kaup, M., Ambinder, R. F., Huff, C. A., Matsui, W., Bolaños-Meade, J., Borrello, I., Powell, J. D., Harrington, E., Warnock, S., Flowers, M., Brodsky, R. A., . . . Fuchs, E. J. (2008). HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2008.03.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.